GNI  Group Ltd. Logo

GNI Group Ltd.

Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.

2160 | T

Overview

Corporate Details

ISIN(s):
JP3386370005
LEI:
Country:
Japan
Address:
中央区日本橋本町二丁目2番2号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

GNI Group Ltd. is a multinational, vertically integrated biopharmaceutical company engaged in the research, clinical development, manufacturing, and commercialization of pharmaceutical drugs and medical devices. The company focuses on developing novel treatments for intractable conditions with unmet medical needs, particularly in the areas of cancer and inflammatory diseases. With core operations spanning Japan, China, and the US, GNI Group leverages genetic analysis technology in its drug discovery pipeline. Its key commercial products include Etuary (pirfenidone) for the treatment of idiopathic pulmonary fibrosis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 10:05
Report Publication Announcement
確認書
Japanese 10.0 KB
2025-08-14 09:30
Interim Report
半期報告書-第25期(2025/01/01-2025/12/31)
Japanese 296.9 KB
2025-07-25 04:00
Share Issue/Capital Change
訂正臨時報告書
Japanese 28.9 KB
2025-07-24 10:09
Regulatory News Service
訂正臨時報告書
Japanese 40.7 KB
2025-04-23 09:00
Share Issue/Capital Change
臨時報告書
Japanese 32.7 KB
2025-03-31 09:00
Registration Form
確認書
Japanese 8.2 KB
2025-03-31 09:00
Governance Information
内部統制報告書-第24期(2024/01/01-2024/12/31)
Japanese 22.2 KB
2025-03-31 09:00
Annual Report
有価証券報告書-第24期(2024/01/01-2024/12/31)
Japanese 1.2 MB
2025-03-28 03:30
Post-Annual General Meeting Information
臨時報告書
Japanese 21.6 KB
2024-08-14 10:08
Regulatory News Service
臨時報告書
Japanese 19.0 KB
2024-08-14 09:26
Interim Report
半期報告書-第24期(2024/01/01-2024/12/31)
Japanese 301.9 KB
2024-08-14 09:26
Report Publication Announcement
確認書
Japanese 10.0 KB
2024-07-02 08:00
Major Shareholding Notification
訂正報告書(大量保有報告書・変更報告書)
Japanese 51.9 KB
2024-06-28 09:00
Major Shareholding Notification
大量保有報告書
Japanese 52.6 KB
2024-05-30 09:30
Share Issue/Capital Change
臨時報告書
Japanese 32.3 KB

Automate Your Workflow. Get a real-time feed of all GNI Group Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GNI Group Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GNI Group Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Benitec Biopharma Inc. Logo
Develops ddRNAi gene therapies to silence genes causing chronic, life-threatening diseases.
United States of America
BNTC
BeOne Medicines Ltd. Logo
Develops innovative and accessible cancer treatments for patients worldwide.
United States of America
ONC
BGM Group Ltd. Logo
A pharma holding co. making APIs & TCM derivatives via bio-fermentation and extraction.
United States of America
BGM
Bicara Therapeutics Inc. Logo
Developing first-in-class, dual-action bifunctional therapies for solid tumor patients.
United States of America
BCAX
BICYCLE THERAPEUTICS PLC Logo
Developing novel bicyclic peptide medicines to precisely target hard-to-treat cancers.
United States of America
BCYC
BIFIDO. Co. Ltd Logo
Biotech firm specializing in microbiome R&D for functional foods and cosmeceuticals.
South Korea
238200
BioAge Labs, Inc. Logo
Develops therapies for metabolic diseases like obesity by targeting the biology of human aging.
United States of America
BIOA
BioArctic Logo
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
Sweden
BIOA
BioAtla, Inc. Logo
Developing safer, conditionally active antibody therapies for solid tumor cancers.
United States of America
BCAB
BioCardia, Inc. Logo
Developing regenerative cell therapies for cardiovascular and pulmonary diseases.
United States of America
BCDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.